Hyaluronic acid encapsulated aminated mesoporous silica nanoparticles for pH‐responsive delivery of methotrexate and release kinetics

Abstract

A simple drug controlled delivery system is facilely designed for pH-responsive delivery of methotrexate (MTX), an anticancer drug. Aminated mesoporous silica nanoparticles (AMSNs) were first synthesized for the loading of MTX, and then the MTX-loaded AMSN (AMSN-MTX) was encapsulated with hyaluronic acid (HA) through electrostatic attractions. Successful preparation of the HAencapsulated AMSN-MTX (AMSN-MTX-HA) is confirmed by different characterizations such as scanning electron microscopy, Fourier transform infrared, x-ray diffraction, and so on. Because the protonation/deprotonation of HA is closely related to pH, the electrostatic interactions between HA and AMSN depend closely on the pH of the medium and thus pH-responsive delivery of MTX is achieved. The release kinetic data of MTX from the carrier fit well to Higuchi and Korsmeyer-Peppas models. Cell experiments indicate that the developed AMSN-MTX-HA displays high inhibitory effect on hepatoma (SMMC-7721) cells while the drug-free carrier of AMSN-HA has good biocompatibility.

Kappa-carrageenan and sodium alginate-based pH-responsive hydrogels for controlled release of methotrexate

“…The value of slope ( n ) is 0.921 computed by the Korsmeyer–Peppas model, which is greater than 0.89, which confirmed super case II transport of MTX from the hydrogel matrix [59]. The value of n 0.921 indicated that there is stress and transition of states in polymeric networks owing to the swelling, which are accountable for MTX release in PBS as also reported in the literature [54,60].…”

A biodegradable drug‐controlled delivery system based on mesoporous manganese dioxide and poly(dopamine)

“…At specific time intervals (1 h), 4 mL of the PBS was taken out to quality the released MTX, and an equal volume of fresh PBS was added for replenishment. According to the UV spectra of MTX at different concentrations and the standard curve of MTX determined at the wavelength of 302 nm (Figure S1), the cumulative release of MTX at different pH values was determined by the following formula: Cumulative release (%) = [(80 C MTX( n ) + ∑4 C MTX( n –1) )]/ M 0 × 100%, 28,29 where C MTX( n ) and C MTX( n –1) stand respectively for the concentrations of MTX at n and ( n – 1) times, 80 is the total volume of PBS (mL), 4 is the volume of PBS (mL) taken out at specific time intervals, and M 0 is the mass of MTX encapsulated in the mMnO 2 ‐MTX‐PDA.…”

Nanocarriers for methotrexate delivery/codelivery in the frame of cancer diagnostics and treatment: a review

“…In vitro drug release studies showed that the release of ACL and MTX was rapid in the early 12 h (over 25%), then slower and at last the release was sustained over 168 h. The drug bioavailability when LPHNP was used as carrier was greater than free MTX and ACL. It was reported that the therapeutic activity of MTX was improved by ACL and the inhibitory effect of MTX/ACL-loaded LPHNPs on cancer growth in a breast cancer mouse model was greater as compared to the simple combination of free MTX and ACL or MTX (Teixeira et al, 2017;Rui et al, 2022).…”